Data Sheet | May 29, 2025
Sapient Tumor Proteomics
Get the Resource
Download NowSapient’s mass spectrometry-based tumor proteomics workflows offer an in-depth, dynamic, and unbiased view of molecular effectors within cancer cells, delivering high-specificity, quantitative measures to characterize proteins and their modifications expressed in individual tumors.
Our tumor proteomics method measures 12,000+ protein groups for deep characterization of cell surface protein (antigen) expression as well as intracellular proteins central to cellular function, structure, and signaling. In addition, Sapient’s mass spectrometry workflows enable capture of key protein variants and isoforms (proteoforms) including established and novel post-translational modifications (PTMs) as well as emerging non-canonical proteins that are highly specific to the cancer state.
These established workflows are also leveraged to assay normal tissue adjacent to the tumor site as well as remote normal tissues, as a means for deep interrogation of proteins and proteoforms that are differentially expressed between tumor and normal tissue. This provides a path to identify robust drug targets and assess potential on-target, off-tissue side effects.
Sapient has also annotated hundreds of key pathways and processes that are well represented in tumor proteomics data, to illuminate the complex interactions of proteins and signaling pathways that drive tumorigenesis and to identify key protein targets for emerging therapeutics.
Download the data sheet to see how we deliver robust, reproducible measures across the broad tumor proteome with differentiated insight delivery including:
- DynamiQ™ tumor and tissue database: to further enable your studies, we have established a database containing comprehensive proteomics measures across a key panel of normal human tissues. We use these measures to identify differentially expressed proteins and proteoforms in tumors and enable discovery and/or validation of key drug targets.
- Biological pathways and drug target analyses: Our biocomputational team interprets generated tumor proteomics data to map signaling pathways, explore differentially expressed oncoproteins, and identify novel drug targets for emerging cancer therapeutics.
- Development of targeted liquid biopsy assays: We can couple our tumor proteomics measures with Sapient’s plasma proteomics workflows to develop liquid biopsies that assay tumor-derived proteins and peptides in blood circulation.